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Objective: Expression profile analysis using endomyocardial biopsy specimens from
patients with cardiomyopathies promises to improve the differential diagnosis of heart
failure.
Methods: In this study, left ventricular endomyocardial biopsy specimens were ob-
tained from 50 patients and histopathologically classified according to the World
Heart Federation Task Force criteria as having dilated cardiomyopathy (n 5 17), in-
flammatory cardiomyopathy (n 5 11), myocarditis (n 5 15), or pericarditis (n 5 7).
Microarrays were performed by hybridization of synthesized complementary DNA
against a Lab-Arraytor60-combi microarray (SIRS-Lab, Jena, Switzerland). Differen-
tially expressed genes were clustered hierarchically according to their variation in
hybridization signals.
Results: In samples from patients with dilated cardiomyopathy, two different types of
gene expression profiles were distinguishable. One pattern was unique for dilated car-
diomyopathy and inflammatory cardiomyopathy, respectively, and the other more
closely resembled that seen in samples from inflammatory heart disease. Additionally,
we confirmed the microarray data by showing that dilated cardiomyopathy is associ-
ated with a reduced myocardial toll-like receptor 9 expression that resulted from pro-
gressive loss of functional cardiomyocytes. Taken together, our data demonstrate the
utility and validity of microarrays from endomyocardial biopsy specimens in detecting
subentities of dilated cardiomyopathy that do not differ histopathologically, but tran-
scriptionally, from each other. The gene expression profile observed in one subgroup
of patients with dilated cardiomyopathy is indicative of ongoing immune activation,
albeit infiltrating immunocompetent cells were not detected histopathologically.
Conclusion: Thus, our transcriptional data indicate that dilated cardiomyopathy con-
stitutes a heterogeneous disease with an broad overlap to inflammatory heart disease.
H
eart transplantation is the sole surgical option for selected patients with se-
vere cardiomyopathy who do not respond to drug therapy. Accurate clinical
assessment is obligatory to decide which patients will benefit from heart
transplantation. Several studies have been carried out to determine unfavorable prog-
noses and to provide an early indication for cardiac transplantation. Despite recent ad-
vances in our pathophysiologic knowledge of end-stage heart disease, the differential
diagnosis of nonischemic cardiomyopathies still remains a challenge for the clinician,
particularly in early stages of the disease.1,2
Dilated cardiomyopathy (DCM), a leading cause of heart failure and heart trans-
plantation, is characterized by dilatation and impaired contraction of the left or both ven-
tricles; it may be idiopathic, familial/genetic, viral, and/or immune. Various pathogenic
human viruses have been identified as causative agents for myocardial damage, in partic-
ular parvovirus B19, enteroviruses (especially Coxsackie B virus), adenoviruses, and her-
pesviruses including cytomegalovirus.3-6 Replication of viral genomes resulting in
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PAbbreviations and Acronyms
cDNA 5 complementary DNA
DCM 5 dilated cardiomyopathy
DCMi 5 dilated cardiomyopathy with inflammation
LV 5 left ventricular
mRNA 5 messenger RNA
RT-PCR 5 reverse-transcriptase polymerase chain
reaction
TLR9 5 toll-like receptor 9
a transient phase of myocytolysis is usually controlled by an
appropriate immune reaction directed at viral clearance.
However, a complete elimination of the replicating virus is
not achieved in all cases, whereas in others the viral genome
persists without productive replication, resulting in a period
of disease inactivity in which the patient often improves or
completely recovers. Most patients experience exclusively
this transient phase of viral infection, as the virus is being
cleared with little or no sequelae. Patients usually seek med-
ical care at this stage because of congestive heart failure and
the occurrence of ventricular arrhythmias. However, even in
these patients the harmful immune activation usually dissi-
pates. Tissue remodeling continues in only a minority of
affected individuals, resulting in the ongoing loss of contrac-
tile myocardium.2 In the latter case, the disease progresses
into DCM and clinical signs of chronic heart failure develop
owing to impaired systolic and diastolic function of the left
ventricle. According to this postulated model of disease pro-
gression, the acute inflammation with infiltrating immuno-
competent cells finally leads to a remodeled heart organ
with predominant reparative fibrosis and, if any, only spare
and focally distributed persisting cellular infiltrates.
Given that the prognosis of patients varies substantially
depending on the underlying etiology, early assessment of
an accurate diagnosis for patients with new-onset heart fail-
ure is of considerable therapeutic importance. The use of car-
diac biomarkers or modern noninvasive imaging techniques
including magnetic resonance imaging is limited for diagnos-
tic evaluation because of their relatively low sensitivity and
specificity as compared with biopsy-proven methods.2,3,7 En-
domyocardial biopsy has been shown to refine the diagnostic
procedure, especially in patients with rapidly progressive
heart failure that is refractory to conventional therapeutic
strategies or if progressive conduction abnormalities or life-
threatening ventricular arrhythmias occur.7 Despite the often
patchy nature of acute myocardial inflammation, which con-
tributes to the underdiagnosis owing to sampling error, endo-
myocardial biopsy is still regarded as the gold standard for
the antemortem diagnosis of myocarditis.3,7,8 The immuno-
histochemical assessment of endomyocardial biopsy samples
has ameliorated the early detection of inflammatory tissue re-
actions in the heart.4,6,9-11 However, the number of cardiac-The Journal of Thospecific epitopes to be tested is restricted depending on the
avidity and availability of the corresponding antibodies. Recent
advances in microarray technology allow measuring the ex-
pression of thousands of genes simultaneously in a defined
small tissue sample.12-14 Thus, we asked whether microchip
technology is principally suitable to distinguish myocarditis
from other heart diseases in a diagnostic setting. In particular,
we were interested to determine whether gene expression pro-
filing from endomyocardial biopsy tissue adds further informa-
tion for the identification of patients with cardiomyopathies.
Patients and Methods
Patient Selection and Diagnosis of Heart Disease
Patients with signs of heart failure, who had been referred to our hos-
pital for further diagnostic investigation because of suspected in-
flammatory heart disease, were enrolled in our study. The patients
usually had a history of recent onset of cardiac arrhythmias, unde-
fined electrocardiographic abnormalities, and atypical chest pain
suggesting nonischemic cardiomyopathy and/or myocardial inflam-
mation. Inclusion criteria for participating in the studywere a histolog-
ically proven diagnosis of one of the following four cardiac diagnoses:
pericarditis, myocarditis, and dilated cardiomyopathy with or without
inflammation (DCM and DCMi, respectively). For all study patients
the accurate cardiologic diagnosis was obtained before the microchip
assays were performed. Patients with pericarditis usually had a hemo-
dynamically relevant pericardial effusion and/or typical electrocardio-
graphic alterations.Myocarditis was defined as an inflammation of the
heart according to the World Heart Federation criteria ($14 lympho-
cytes andmacrophages per squaremillimeter) independent of the clin-
ical phenotype or the presence of heart failure or ventricular
dilatation.15,16 DCMi was diagnosed if, in addition to histologic signs
of inflammation, impaired left ventricular (LV) function was proven
by echocardiography (LV end-diastolic diameter . 55 mm, LV
end-diastolic volume index . 100 mL/m2, or LV ejection fraction
, 50%).16 If no inflammation was detectable, patients with impaired
LV function were classified as having DCM.
In each patient, coronary angiography was performed to exclude
significant coronary artery disease with a luminal narrowing of ma-
jor arteries of 50% or more. For all patients, the prevalence of the
parvovirus B19 genome was tested as described before.4 Patients
with suspected inflammatory heart disease who underwent endo-
myocardial biopsy for therapeutic and/or diagnostic reasons were
asked to participate in our study. If they agreed, written informed
consent was obtained. The investigation conforms with the princi-
ples outlined in the Declaration of Helsinki. This study protocol
was approved by the local ethical review board.
Tissue Collection
From each patient undergoing cardiac catheterization, multiple LV
endomyocardial specimens were obtained with a flexible bioptome.
Each tissue specimen was then divided into two parts: one for histo-
pathologic examination and the other for RNA analyses. The biopsy
specimens were immediately snap-frozen in liquid nitrogen and
banked at 280C for storage until further use.
Immunohistochemical Stainings
Frozen sections of the banked endomyocardial tissue samples were
cut (5 mm) and stained immunohistochemically for the detection ofracic and Cardiovascular Surgery c Volume 136, Number 2 361
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CSPinfiltrating cells. Monoclonal antibodies against CD3, CD4, and
CD11c, all obtained from Dako Diagnostics Ltd (Copenhagen,
Denmark), were used in this study. Avidin–biotin double sandwich
technique (Vectastain Elite ABC Kit; Vector Laboratories, Inc, Bur-
lingame, Calif) was used in combination with a monoclonal anti-
body against the endothelial antigen EN 4 (Sanbio BV, AmUden,
The Netherlands) to distinguish infiltrating lymphocytes (red stain-
ing) adjacent to myocytes from those located nearby or inside intra-
myocardial vessels and capillaries (blue staining). Toll-like receptor
9 (TLR9) was stained with a rabbit polyclonal antibody (H-100)
purchased from Santa Cruz Biotechnology (Santa Cruz, Calif).
Detection of bound immunoglobulins was achieved with the ABC
method employing biotinylated secondary antibodies and avidin–
horseradish peroxidase complexes (Vectastain Elite ABC Kit
from Vector Laboratories). Diaminobenzidine producing a brown
reaction product was used as a substrate for visualization of the en-
zyme reaction. Finally, the sections were counterstained with
Mayer’s hematoxylin.
RNA Isolation, Complementary DNA Synthesis
and Microarray Hybridization
Total RNA was extracted from endomyocardial biopsy specimens
or autoptic heart tissue using the Qiagen RNeasy Kit and eluted in
a volume of 30 mL of sterile water as recommended by the manufac-
turer. RNA concentrations were determined spectrometrically at
a wavelength of 260 nm. Because of minimal total RNA in the sam-
ples, complementary DNA (cDNA) synthesis was performed by the
BD Super SMART cDNA synthesis technology (BD Biosciences,
Franklin Lakes, NJ) according to the manufacturer’s instructions.
Reverse transcription was in the presence of aminoallyl-dUTP and
cDNA was labeled by the use of the Alexa Fluor 647 system (Invi-
trogen, Carlsbad, Calif). Alexa Fluor 647–labeled cDNA was cohy-
bridized with pooled Alexa Fluor 555–labeled cDNA obtained from
6 autoptic hearts from patients who died of noncardiac diseases and
served as control samples. Synthesis of cDNA included a DNase I
treatment (Promega Corporation, Madison, Wis) to prevent cellular
DNA contamination in the polymerase chain reaction (PCR). Each
RNA pair (sample vs reference) was hybridized against a Lab-Ar-
raytor60-combi microarray, comprising 578 probes for 556 human
genes involved in inflammatory processes and 22 positive/negative
controls (SIRS-Lab, Jena, Switzerland). After incubation in a form-
amide-based hybridization buffer for 10 hours at 42C, microarrays
were washed and dried. Hybridization signal intensities were mea-
sured with a GenePix scanner (Axon Instruments, division of Mo-
lecular Dynamics, Sunnyvale, Calif).
Microarray Data Pre-processing
Data pre-processing included the following 4 steps: (1) spot detec-
tion and quantification, (2) spot flagging according to the defined
signal-to-noise threshold value, (3) correction of systematic bias in-
cluding the normalization and the variance-stabilized transformation
of raw signals, and (4) averaging of printing replicates. For the first 2
steps, the GenePix Analysis Software was used. The raw expression
signals for each spot were quantified as the median spot intensity in
the red and green channel, respectively. The spots were flagged cor-
responding to the settings of the GenePix Software. For the third
step the approach of Huber and colleagues17 was used and the addi-
tive and multiplicative errors were estimated. The normalized sig-
nals were transformed by the arcsinh function. Per gene, replicates362 The Journal of Thoracic and Cardiovascular Surgery c Awith the highest flag value were selected and the corresponding
signal intensities were averaged.
Statistical Data Analysis
In the analysis, the gene expression profiles of 50 patients with suf-
ficient hybridization quality were included. The statistical analysis
was performed for 481 reliable genes, that is, genes with detectable
signal intensity and sufficient variation throughout the experiment.
Missing values were imputed employing the k-nearest neighbor al-
gorithm with k 5 15.18 A vector of p values was obtained from
a multivariate permutation test based on 1-way analysis of variance
statistics, where the effect of the disease type (DCM, DCMi, myo-
carditis, and pericarditis) was investigated for each gene. Genes
with statistically significant differences were identified by tuning
the q value, thus controlling the positive false discovery rate.19
The corresponding approach also allowed for estimation of the pro-
portion of differentially expressed genes. The gene expression pat-
terns of selected genes were ordered by hierarchical cluster
algorithm with Euclidean distance and averaged linkage method.
Reverse-transcriptase PCR (RT-PCR)
Verification of the microarray results was confirmed by real-time
PCR using the SYBR-Green method (Invitrogen). Gene-specific
primers were designed using Primer 3 software (Applied Biosys-
tems, Foster City, Calif) to amplify fragments of about 200 base
pairs in length. The reverse-transcriptase (RT) PCR reactions were
carried out in a total volume of 25 mL, containing 25 ng messenger
RNA (mRNA), 7.5 mmol/L of each specific primer pair, and 2.5 mL
of SYBR Green. The following protocol was applied: reverse tran-
scription at 50C for 30 minutes followed by a denaturation step at
95C 15 minutes, and 40 cycles of denaturation at 95C for 45 sec-
onds, annealing at 60C for 45 seconds, and extension at 72C for 45
seconds. A melting curve analysis was run after final amplification
via a temperature gradient from 55C to 94C in 0.5C increment
steps measuring fluorescence at each temperature for a period of
10 seconds. All reactions were carried out in at least duplicate for
each sample. The relative expression of a transcript was calculated
as the ratio between the specific transcript level and the level of gapdh
as determined for each sample. Using the Bio-Rad iQ-iCycler system
software (Bio-Rad Laboratories, Hercules, Calif), the threshold (Ct) at
which the cycle numbers were measured was adjusted to areas of
exponential amplification of the traces. The DD-method was used to
determine comparative relative expression levels by applying the
formula 22(DCt target 2 DCt reference sample), as described previously.20
Results
Characterization of the Study Population
The total study population included 50 patients. Among
them, DCM was diagnosed in 17 study participants and
DCMi in 11 subjects. The diagnosis of myocarditis was con-
firmed in 15 patients. A fourth group consisting of 7 subjects
with pericardial effusion was included in the study, in which
endomyocardial biopsy had revealed no pathologic signs on
histologic examination. This group of patients was therefore
diagnosed to have pericarditis. With the exception of the lat-
ter group, the majority of all study participants in each group
were men (DCM, 89.9%; DCMi, 90.0%; and myocarditis,ugust 2008
Ruppert et al Cardiopulmonary Support and PhysiologyTABLE 1. Patient characteristics
DCM DCMi Myocarditis Pericarditis
Age (y) 48.8 6 14.6 45.8 6 9.6 41.7 6 19.7 50.6 6 21.7
Sex (F/M) 2/15 1/8 3/12 4/3
EF (%) 27.2 6 10.6* 27.8 6 10.0* 69.1 6 14.8 65.1 6 22.5
LVEDD (mm) 67.3 6 6.9* 64.5 6 7.0* 50.2 6 5.3 45.1 6 4.2
Parvovirus B19 (pos./neg.) 4/13 4/5 7/8 3/4
EF, Ejection fraction; LVEDD, left ventricular end-diastolic diameter; pos./neg., positive/negative. *P, .05; difference between patient groups having myocar-
ditis or pericarditis.CS
P82.3%). As expected, the echocardiographically measured
LV end-diastolic diameter was significantly elevated in
both DCM and DCMi patients (67.3 6 6.9 mm and 64.5 6
7.0 mm, respectively) as compared with patients with myo-
carditis or pericarditis (50.2 6 5.3 mm and 45.1 6
4.2 mm; P , .05). Similarly, LV ejection fraction differed
significantly between DCM and DCMi patients on the one
hand (27.2% 6 10.6% and 27.8% 6 9.6%, respectively)
and patients with myocarditis or pericarditis on the other
(69.1% 6 14.8% and 65.1% 6 22.5%; P , .05). Further
details on the study population are presented in Table 1.
Immunohistochemical Detection of
Immunocompetent Cells in Biopsy Tissue
Immunohistochemistry was performed in biopsy samples to
detect immunocompetent cells in the myocardium, thereby
distinguishing between different entities of heart diseases.
Figure 1 demonstrates the presence of CD3-positive T cells
in mononuclear infiltrates in patients with myocarditis,
whereas in patients with DCM and pericarditis stainingThe Journal of Thorwith anti-CD3 antibody was usually negative (Figure 1, A).
In endomyocardial biopsy tissue from patients with DCMi,
CD3-positive T cells only occasionally were detected scat-
tered throughout the section. Similarly, CD4-positive cells
were detected in specimens from inflammatory heart disease
and infrequently in patients with DCMi but were generally
absent in DCM and pericarditis (Figure 1, B andC). Dendritic
cells expressing CD11c were most often detected in inflam-
matory infiltrates from patients with myocarditis (Figure 1,
D). However, dendritic cells were also detected but less fre-
quently in tissue specimens from the remaining patient
groups.
Differential Gene Expression in Different Heart
Diseases
Next, we performed microarrays to explore putative differ-
ences in the expression profile of genes involved in inflamma-
tory reactions among the four entities of heart disease. A list of
genes that showed differential expression between the patient
groups was generated by ranking the genes according to theFigure 1. Immunohistochemical detec-
tion of infiltrating immune cells in endo-
myocardial biopsy samples. Shown are
the localization of CD3- (A) and CD4-
positive T cells (B and C) in patients
with myocarditis (A and B) and DCM
(C), respectively, as well as CD11c-pos-
itive dendritic cells in a patient with
myocarditis (D). Double staining using
a monoclonal antibody against endo-
thelial antigen EN 4 was applied to dis-
tinguish infiltrating lymphocytes (red
staining) from intramyocardial vessels
and capillaries (blue staining). Note
the absence of a positive CD4 immuno-
staining in heart tissue obtained from
a DCM patient (C).acic and Cardiovascular Surgery c Volume 136, Number 2 363
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CSPrelative median expression. We found differences in the gene
expression between the patient groups for approximately 45%
of genes tested. A set of 42 genes with a q value of less than 17
(corresponding to a p value of less than.026) was considered as
being significantly changed (thus 7 false positive decisions
were accepted). Data corresponding to the selected genes are
summarized in Supplemental Table E1 and Figures 2 and 5.
The mean expression of the 6 genes with least q values
(cflar, c3, serca2, serping, cis, and galc) was higher for the
patient groups with myocarditis and pericarditis, respec-
tively, as compared with those with DCMi or DCM. For
the majority of the selected genes the expression level was el-
evated in the patients with myocarditis and pericarditis as
compared with study participants with DCM or DCMi. The
expression of some genes, for example, fos, nppb, map3k,
tnfrsf6, or ppbp, was reduced in the group with pericarditis
when compared with the remaining patient groups. To better
visualize the obtained expression patterns, variations in hy-
bridization signals were ordered by hierarchical clustering.
In Figure 2, the transcription patterns are presented by a col-
ored image and the corresponding dendrogram. It can be seen
in this figure that with respect to the gene expression pattern,
the patient group with DCM encompasses two distinct sub-
groups. Whereas the gene expression in 7 patients of the
DCM group was similar to that observed in myocarditis,
the gene expression in the remaining 10 patients corre-
sponded well to that seen in patients with DCM. Interest-
ingly, the former subgroup of patients with DCM, who
more likely resembled the expression profile of myocarditis
patients, had significantly higher LV shortening fractions
(18.9% 6 6.3% vs 11.3% 6 3.0%; P 5 .003; see Figure 3).
Next, we compared the two DCM subgroups separately
with the DCMi patients for their echocardiographically as-
sessed shortening fraction (for DCMi patients; 16.0% 6
3.2%). Statistical significance was achieved only for the sub-
group of DCM patients with a unique gene expression (P 5
.003), but not for those DCM patients with a gene expression
pattern resembling that of myocarditis (P . .05). No associ-
ation was seen between parvovirus B19 positivity and gene
expression profiling.
Validation of Differentially Expressed Genes Using
RT-PCR
The differential gene expression observed in the microarrays
was verified by two independent measurement methods.
First, we performed real-time RT-PCR from the same set of
tissue samples and compared these results with the findings
from the microarrays. On the basis of biologic considerations
and statistical significance, two genes were selected for RT-
PCR measurements: serca and tlr9. The sarcoplasmic reticu-
lum Ca21-ATPase Serca was included in the microarray and
chosen for RT-PCR validation, because it is widely known
that Serca expression is down-regulated in the hearts of pa-
tients with DCM.21 The second gene included for validation364 The Journal of Thoracic and Cardiovascular Surgery c Auof the microarray results by quantitative RT-PCR was tlr9.
Expression of gapdh was not significantly changed between
the samples and therefore gapdh served as a control for nor-
malization of the RT-PCR measurements.
Our RT-PCR results confirmed that serca expression in
DCM and DCMi patients was down-regulated as compared
with that in patients with pericarditis or myocarditis
(Figure 4, B). The decreased serca expression in the former
patient groups as measured by RT-PCR correlated well with
the results from the microchip experiment. Similarly, ex-
pression of tlr9 coding for TLR9 was significantly reduced
in DCM patients as judged by both RT-PCR and microar-
rays (Figure 4, A). The expression level of tlr9 was interme-
diate in DCMi patients and high in patients with acute
inflammatory heart disease. Thus, our data showed that
the RT-PCR results generally paralleled those seen by mi-
croarray analysis.
Expression of TLR9 in Endomyocardial Biopsy Tissue
Next, we tested whether immunohistochemical stainings
confirmed the expression data obtained from the microarrays
(Figure 5). Since microarray and RT-PCR techniques both re-
vealed down-regulation of tlr9 in DCM and DCMi patients,
we asked whether the reduced TLR9 expression was also de-
tectable at the level of protein expression. In immunohisto-
chemical stainings using a specific anti-TLR9 antibody, we
confirmed the expression patterns described above at the
mRNA level. TLR9 was localized predominantly in the cyto-
sol of cardiomyocytes but was generally absent in noncardio-
myoctes. It was found that the staining intensity of TLR9
immunopositivity in biopsy specimens from patients with
DCM was significantly lower as compared with the other
three disease entities (Figure 5, D). There was a significantly
higher expression of TLR9 in tissue samples from myocardi-
tis and pericarditis patients (Figure 5, A and B). Also here
TLR9-positive cells were exclusively cardiomyocytes as
judged by their characteristic shape and the presence of a con-
tractile apparatus, whereas lymphocytes or antigen-present-
ing cells comprising inflammatory infiltrates were typically
negative. Biopsy samples from patients with DCMi often
showed an intermediate staining pattern (Figure 5, C). Taken
together, immunohistochemical detection of TLR9 used here
as an independent method for assessing gene expression con-
firmed the differential gene expression pattern between the
distinct disease conditions, as had already been revealed
before by microarray and RT-PCR techniques.
Discussion
In this study, we compared the global gene expression pro-
files from four clinically and histopathologically defined en-
tities of heart disease using a custom-designed DNA
microarray technology in an attempt to identify potential mo-
lecular markers that facilitate the differential diagnosis of car-
diomyopathies. The set of genes tested here for cardiacgust 2008
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PFigure 2. Gene expression characteris-
tics in patients with different clinical
diagnoses. From statistical comparison,
42 genes were identified that signifi-
cantly differed between the patient
groups. The gene expression patterns
of these genes were ordered by hierar-
chical cluster algorithm with Euclidian
distance and averaged linkage method.
Each gene is represented by a single
row of colored boxes and each sample
by a single column. The associated
colors represent variance-normalized
expression for individual genes. While
the intensity of red color indicates a rel-
ative expression greater than the mean,
green indicates a decreased expresion
level compared with the mean. (B) Dis-
tribution of the gene expression
throughout the experiment. To minimize
the number of false positives, we ex-
cluded such genes from the statistical
analysis whose mean expression inten-
sity were less than those of any the neg-
ative control or whose expression
variation throughout the experiment
was less than those of the most positive
controls. (C) Statistical comparison of
the gene expression patterns. Left
panel, Histogram of p values obtained
from the statistical test. While the line
at the height of ho512 is the histogram
expected portion of null p values if none
gene was differentially expressed, the
line at the height of h156.9 is the histo-
gram of the estimated portion of null p
values. Middle panel, The q values ver-
sus their respective p values. Right
panel, The number of genes considered
as being differentially expressed versus
the respective q values. For a q value
closed to 0.17 a particular increase in
the curve can be observed.The Journal of Thoracic and Cardiovascular Surgery c Volume 136, Number 2 365
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the corresponding gene products in executing inflammatory
reactions. The data presented demonstrate that hierarchical
gene clustering in microarray analysis allows for the identifi-
cation of distinct gene expression patterns that distinguish
different heart diseases from each other. Despite considerable
interindividual variability, our microarray results show that
in the myocardium of patients with DCM and DCMi, a panel
of genes involved in immune regulation is differentially ex-
pressed as compared with that in patients with myocarditis
or pericarditis. Within the group of DCM patients we ob-
served two different expression patterns for inflammatory
markers, which were clearly distinguishable from each other.
One gene expression profile resembled more closely that seen
also in patients with myocarditis, whereas the other pattern
was unique for DCM and DCMi patients. Individuals exhib-
iting the latter type of gene expression had a significantly re-
duced LV shortening fraction as compared with those from
Figure 3. The gene expression profiles between two subgroups of
DCM patients differ significantly depending on the severity of im-
paired LV systolic function. Echocardiographically measured
shortening fractions (A) and ejection fractions (EF) (B) are pre-
sented separately for both subgroups of DCM patients with dis-
tinct gene expression patterns.366 The Journal of Thoracic and Cardiovascular Surgery c Authe former subgroup, indicating that their LV systolic func-
tion was more profoundly impaired. These data suggest
that DCM patients with a gene expression pattern more
closely resembling that of myocarditis may be classified as
belonging to an intermediate subgroup that is transcription-
ally, but not necessarily histopathologically, distinguishable
from subjects with a DCM-specific gene expression profile.
Additionally, our microarray results indicate that there is
a substantial overlap in gene expression profiles between
the subgroup of DCM patients with only slightly impaired
LV systolic function and those diagnosed as DCMi. In the
subgroup of DCM patients exhibiting a unique gene expres-
sion pattern, the shortening fraction was significantly more
reduced as compared with that of patients with a transcription
pattern resembling that of myocarditis. Thus, belonging to
a transcriptionally defined DCM subgroup seems to be asso-
ciated with a reduced systolic function of the left ventricle.
The different myocardial gene expression profiles seen in
both DCM subgroups appear to more likely reflect the sever-
ity of LV impairment than the presence of a still ongoing im-
mune reaction, which is undetectable in the diverse
immunohistochemical techniques applied here for the detec-
tion of infiltrating cells.
The expression levels of the selected genes were generally
more decreased in DCM and DCMi patients as compared
with those diagnosed as either myocarditis or pericarditis.
This finding was not unexpected inasmuch as the genes se-
lected for the microarrays were chosen with respect to their
engagement in inflammatory processes. However, it is un-
clear whether the reduced activation level found here for nu-
merous genes simply reflects the nosologic heterogeneity and
clinical severity of the disease or whether it indicates a more
profound alteration in transcriptional activity that accom-
panies the phenotypic dedifferentiation process of cardio-
myocytes. Nevertheless, our microarray results allow DCM
patients to be divided into two distinct subgroups that differ
considerably with respect to the transcriptional activation of
inflammatory genes. Thus, microarrays obtained from endo-
myocardial biopsy tissue add further information for the sub-
classification of DCM patients that are not covered by
conventional methods of gene expression measurements.
Additionally, we tested the microarray technique for
screening novel markers whose expression is specifically
changed in DCM. Recently, this approach has been success-
fully applied in numerous studies.14,22-31 Here we focused on
a gene product that has not been related to the pathogenesis of
DCM so far, but whose expression was gradually reduced as
determined in our microarrays. The gene coding for TLR9
was identified as such a marker that is significantly down-reg-
ulated in DCM patients. Interestingly, our RT-PCR results
confirmed that the induction of the tlr9 gene is critically im-
paired in DCM and DCMi patients, whereas significantly
higher expression levels were measured in myocarditis and
pericarditis patients. Expression of TLR9 was restricted togust 2008
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PFigure 4. Comparison of expression data between microarrays and RT-PCR measurements. Shown are the microar-
ray (left) and RT-PCR results (right) for the expression of tlr9 coding for toll-like receptor 9 (A) and serca (B) in
patients grouped with respect to the underlying heart disease. Note that serca and tlr9 mRNA are both down-reg-
ulated in DCM and DCMi as compared with patients with myocarditis or pericarditis and that these findings were
independent of the particular technique used.differentiated cardiomyocytes as observed immunohisto-
chemically, whereas nonmyocytes usually expressed much
lower, if any, immunodetectable TLR9. With increasing
amounts of fibrotic components, the signal intensity in the
anti-TLR9 stained tissue specimens was critically decreased,
as was observed in DCM patients. Thus, three independent
techniques demonstrated down-regulation of the tlr9 gene as
was first revealed in the microarray analyses and later
confirmed both at the mRNA and protein level. Members
of the toll-like receptor family such as TLR9 have been im-
plicated in the recognition of exogenous and endogenous li-
gands and activate the nuclear factor kB pathway.32 The
high expression level of TLR9 in morphologically intact
cardiomyocytes suggests a functional role of these cells in
the recognition of the cognate ligand, which is unmethylated
CpG DNA.The Journal of ThorOur data suggest that implementing microarray-based in-
formation on gene expression broadens our understanding for
the pathogenesis and subclassification of DCM and related
diseases. RNA amplification protocols combined with gene
expression profiling appear to refine the clinical diagnosis
of cardiomyopathies. Novel disease-associated markers
may be identified that are suitable for the screening of pa-
tients with otherwise unexplained heart disease. Advanced
DNAmicrochip technology promises to identify target genes
of potential therapeutic interest that are involved in diverse
pathologic pathways such as remodeling and apoptosis.
The expression of these genes may then be specifically mod-
ulated by gene-targeting approaches that are currently under
development.
Taken together, our microarray analysis based on genes
involved in immune regulation allows for the distinctionacic and Cardiovascular Surgery c Volume 136, Number 2 367
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CSPFigure 5. Decreased expression of toll-
like receptor 9 (TLR9) in DCM and DCMi
patients as shown by immunohisto-
chemistry. Endomyocardial biopsy
specimens were stained for the pres-
ence of TLR9 in patients diagnosed as
myocarditis (A), pericarditis (B), DCMi
(C), and DCM (D), respectively.between different entities of DCM. In a subgroup of DCM
patients with impaired LV function, we detected evidence
of continuous immune activation, as judged by the elevated
expression of inflammatory genes. Thus, despite the absence
of infiltrating immunocompetent cells, our transcriptional
data demonstrate ongoing activation of the immune system
in this DCM subgroup. The robustness of the gene expression
signatures shown here can be successfully applied to identify
novel disease-associated markers, such as TLR9, that are
dysregulated in specific cardiac entities.
We gratefully acknowledge the expert support by Markus Bla¨ss
and Stefan Rußwurm from SIRC Lab for performing microarray
analysis and the excellent technical assistance byMarlies Crombach
and Heike Eckhardt from the University of Marburg.
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CSPTABLE E1. For genes with q< .17 (in ascending) the data are presented as the means6 standard deviations of normalized
and transformed expression signals
Mean 6 SD
Acc.-No Gene symbol DCM DCMi Myocarditis Pericarditis p value q value
NM_003879 CFLAR 0.33 6 0.24 0.16 6 0.28 0.63 6 0.21 0.7 6 0.42 .000 .029
NM_000064 C3 0.06 6 0.1 0.05 6 0.2 0.27 6 0.16 0.24 6 0.17 .000 .029
NM_001681.2 SERCA2 0.88 6 0.41 0.69 6 0.42 1.24 6 0.22 1.37 6 0.36 .000 .029
NM_000062 SERPING1 0.03 6 0.18 0.12 6 0.21 0.35 6 0.22 0.24 6 0.22 .001 .075
NM_001734 C1S 0.18 6 0.17 0.17 6 0.17 0.43 6 0.22 0.3 6 0.04 .002 .113
NM_000153 GALC 0.18 6 0.21 0.02 6 0.21 0.3 6 0.17 0.32 6 0.22 .004 .152
NM_016562 TLR7 0.01 6 0.1 0.0 6 0.09 20.12 6 0.09 20.08 6 0.14 .005 .152
NM_013261.1 PGC-1 0.12 6 0.09 0.07 6 0.1 0.14 6 0.11 0.22 6 0.09 .005 .152
NM_006573 TNFSF13B 20.23 6 0.12 20.08 6 0.09 20.24 6 0.16 20.22 6 0.09 .005 .152
NM_004633 IL1R2 0.03 6 0.05 0.1 6 0.13 20.01 6 0.06 20.03 6 0.11 .006 .152
NM_005252 FOS 0.08 6 0.11 0.09 6 0.09 0.02 6 0.06 20.07 6 0.16 .006 .152
NM_000657 BCL2.2 20.21 6 0.09 20.13 6 0.07 20.27 6 0.09 20.2 6 0.07 .007 .154
NM_080738 EDARADD 0.27 6 0.19 0.22 6 0.19 0.46 6 0.14 0.37 6 0.17 .008 .154
NM_002521.1 NPPB 0.11 6 0.6 20.07 6 0.62 20.26 6 0.57 20.82 6 0.65 .009 .154
NM_006301 MAP3K12 20.07 6 0.07 20.01 6 0.07 20.03 6 0.06 20.18 6 0.22 .010 .154
NM_000201.1 ICAM1 20.08 6 0.09 0.02 6 0.08 20.08 6 0.1 0.02 6 0.09 .010 .154
NM_000874 IFNAR2 0.59 6 0.43 0.36 6 0.28 0.82 6 0.29 0.82 6 0.33 .010 .154
NM_003805 CRADD 0.02 6 0.12 20.04 6 0.12 0.11 6 0.09 0.1 6 0.13 .011 .154
NM_002745 MAPK1.1 0.22 6 0.18 0.15 6 0.13 0.32 6 0.11 0.33 6 0.16 .011 .154
NM_002755 MAP2K1 20.15 6 0.19 20.03 6 0.15 20.02 6 0.28 0.17 6 0.41 .012 .154
NM_019846 CCL28 20.04 6 0.11 0.01 6 0.08 0.07 6 0.16 0 6 0.06 .012 .154
NM_006538 BCL2L11 20.07 6 0.06 20.1 6 0.1 0.01 6 0.08 20.02 6 0.08 .013 .154
NM_017442 TLR9 0.02 6 0.14 0.06 6 0.08 0.14 6 0.09 0.16 6 0.12 .013 .154
NM_001242 TNFRSF7 20.13 6 0.06 20.06 6 0.06 20.07 6 0.09 20.13 6 0.09 .013 .154
NM_000043 TNFRSF6 20.04 6 0.05 20.01 6 0.08 20.06 6 0.1 20.18 6 0.23 .014 .154
NM_000655.2 SELL 20.15 6 0.13 0 6 0.18 20.18 6 0.1 20.15 6 0.16 .014 .154
NM_000543 SMPD1 0.13 6 0.18 0.02 6 0.2 0.26 6 0.15 0.2 6 0.21 .017 .155
NM_002720 PPP4C 20.11 6 0.15 0 6 0.09 20.06 6 0.11 0.04 6 0.04 .017 .155
NM_002188 IL13 0.23 6 0.24 0.11 6 0.17 0.37 6 0.19 0.3 6 0.14 .018 .155
NM_021975 RELA 20.14 6 0.14 20.03 6 0.07 20.11 6 0.11 20.02 6 0.09 .018 .155
NM_004834 MAP4K4 0.34 6 0.29 0.22 6 0.25 0.52 6 0.19 0.53 6 0.31 .018 .155
NM_001350 DAXX 20.01 6 0.09 20.04 6 0.12 0.08 6 0.09 0.05 6 0.14 .018 .155
NM_022740 HIPK2 20.11 6 0.08 20.03 6 0.09 20.16 6 0.1 20.09 6 0.13 .019 .155
NM_004315 ASAH1 20.09 6 0.1 20.06 6 0.13 0.03 6 0.1 0.02 6 0.16 .019 .156
NM_003376 VEGF 0.61 6 0.42 0.43 6 0.29 0.83 6 0.31 0.85 6 0.33 .020 .161
NM_004131 GZMB 20.23 6 0.11 20.14 6 0.06 20.22 6 0.1 20.13 6 0.1 .022 .162
NM_000256.2 MYBPC3 1.02 6 0.43 0.92 6 0.3 1.22 6 0.21 1.35 6 0.17 .022 .162
NM_001225 CASP4 20.14 6 0.11 20.06 6 0.06 20.03 6 0.08 20.12 6 0.12 .023 .162
NM_001824.2 CKM 0.79 6 0.4 0.78 6 0.44 1.1 6 0.28 1.2 6 0.39 .023 .162
NM_002704 PPBP 0.02 6 0.15 0.17 6 0.45 0.06 6 0.16 20.35 6 0.69 .025 .170
NM_032964 CCL15.2 20.03 6 0.1 20.05 6 0.09 0.03 6 0.07 0.05 6 0.06 .025 .170
NM_000611 CD59 0.09 6 0.1 0.04 6 0.12 0.17 6 0.12 0.17 6 0.08 .026 .170
SD, Standard deviation; DCM, dilated cardiomyopathy; DCMi, inflammatory dilated cardiomyopathy.369.e1 The Journal of Thoracic and Cardiovascular Surgery c August 2008
